6b73: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor== | ==Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor== | ||
<StructureSection load='6b73' size='340' side='right' caption='[[6b73]], [[Resolution|resolution]] 3.10Å' scene=''> | <StructureSection load='6b73' size='340' side='right'caption='[[6b73]], [[Resolution|resolution]] 3.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6b73]] is a 4 chain structure with sequence from [ | <table><tr><td colspan='2'>[[6b73]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli], [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6B73 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6B73 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=CVV:N-[(5alpha,6beta)-17-(cyclopropylmethyl)-3-hydroxy-7,8-didehydro-4,5-epoxymorphinan-6-yl]-3-iodobenzamide'>CVV</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.1Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=CVV:N-[(5alpha,6beta)-17-(cyclopropylmethyl)-3-hydroxy-7,8-didehydro-4,5-epoxymorphinan-6-yl]-3-iodobenzamide'>CVV</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6b73 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6b73 OCA], [https://pdbe.org/6b73 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6b73 RCSB], [https://www.ebi.ac.uk/pdbsum/6b73 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6b73 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/C562_ECOLX C562_ECOLX] Electron-transport protein of unknown function.[https://www.uniprot.org/uniprot/OPRK_HUMAN OPRK_HUMAN] G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.<ref>PMID:12004055</ref> <ref>PMID:22437504</ref> <ref>PMID:7624359</ref> <ref>PMID:8060324</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 6b73" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6b73" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Antibody 3D structures|Antibody 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Escherichia coli]] | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Carroll | [[Category: Lama glama]] | ||
[[Category: Che | [[Category: Large Structures]] | ||
[[Category: Cherezov | [[Category: Carroll IF]] | ||
[[Category: Han | [[Category: Che T]] | ||
[[Category: Huang | [[Category: Cherezov V]] | ||
[[Category: Katritch | [[Category: Han GW]] | ||
[[Category: Kormos | [[Category: Huang XP]] | ||
[[Category: Krumm | [[Category: Katritch V]] | ||
[[Category: Lee | [[Category: Kormos C]] | ||
[[Category: Majumdar | [[Category: Krumm BE]] | ||
[[Category: McCorvy | [[Category: Lee MY]] | ||
[[Category: Mosier | [[Category: Majumdar S]] | ||
[[Category: Pardon | [[Category: McCorvy JD]] | ||
[[Category: Pasternak | [[Category: Mosier PD]] | ||
[[Category: Roth | [[Category: Pardon E]] | ||
[[Category: Stevens | [[Category: Pasternak GW]] | ||
[[Category: Steyaert | [[Category: Roth BL]] | ||
[[Category: Strachan | [[Category: Stevens RC]] | ||
[[Category: Tribo | [[Category: Steyaert J]] | ||
[[Category: Uprety | [[Category: Strachan RT]] | ||
[[Category: Vardy | [[Category: Tribo AR]] | ||
[[Category: Wacker | [[Category: Uprety R]] | ||
[[Category: Wang | [[Category: Vardy E]] | ||
[[Category: Zaidi | [[Category: Wacker D]] | ||
[[Category: Wang S]] | |||
[[Category: Zaidi SA]] | |||